久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial americanpharmaceuticalreview
    May 06, 2020
    Lipocine announced that the U.S. Food & Drug Administration (FDA) has accepted the Company's Investigational New Drug application (IND) to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic potential of LPCN 1148.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service